For example, Yuan et al. [127] tested the dual pan-PI3K/mTOR inhibitor PF-04691502 as a single agent in ovarian cancer SKOV3 xenograft models and observed dose-dependent reduction in tumor volume in PIK3CA mutant SKOV3 xenografts, which also correlated with plasma concentration, induced time- and dose-dependent target modulation and following oral administration, and was well tolerated without body weight loss. This evidence concerns the gene PIK3CD and ovarian carcinoma.